Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Swedberg

Showing results (341-350 of 471) with videos related to

Pageof 48
Sort By:
Circulation. Heart Failure|January 26, 2018
Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure): Clinical and Prognostic AssociationsPeter van der Meer, Niels Grote Beverborg, Marc A Pfeffer, et al.
Circulation. Heart Failure|August 9, 2017
Health-Related Quality of Life Outcomes in PARADIGM-HFEldrin F Lewis, Brian L Claggett, John J V McMurray, et al.
European Heart Journal|October 30, 2010
Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failureGaetano M De Ferrari, Harry J G M Crijns, Martin Borggrefe, et al.
Lancet (London, England)|February 16, 2016
Health-care improvements in a financially constrained environmentInger Ekman, Reinhard Busse, Ewout van Ginneken, et al.
JAMA|June 12, 2008
Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fractionNorman C Wang, Aldo P Maggioni, Marvin A Konstam, et al.
Circulation|June 15, 2007
Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programEileen O'Meara, Tim Clayton, Margaret B McEntegart, et al.
Circulation. Heart Failure|February 27, 2016
Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) TrialScott D Solomon, Brian Claggett, Akshay S Desai, et al.
European Journal of Heart Failure|October 23, 2024
Visit-to-visit changes in heart rate in heart failure: A pooled participant-level analysis of the PARADIGM-HF and PARAGON-HF trialsHenri Lu, Brian L Claggett, Milton Packer, et al.
European Journal of Heart Failure|May 16, 2023
Incremental prognostic value of biomarkers in PARADIGM-HFKirsty McDowell, Ross Campbell, Joanne Simpson, et al.
Circulation. Heart Failure|May 4, 2016
Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST TrialAndrew P Ambrosy, Hassan Khan, James E Udelson, et al.
Pageof 48

Showing results (341-350 of 471) with videos related to

Sort By:
Pageof 48
Circulation. Heart Failure|January 26, 2018
Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure): Clinical and Prognostic AssociationsPeter van der Meer, Niels Grote Beverborg, Marc A Pfeffer, et al.
Circulation. Heart Failure|August 9, 2017
Health-Related Quality of Life Outcomes in PARADIGM-HFEldrin F Lewis, Brian L Claggett, John J V McMurray, et al.
European Heart Journal|October 30, 2010
Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failureGaetano M De Ferrari, Harry J G M Crijns, Martin Borggrefe, et al.
Lancet (London, England)|February 16, 2016
Health-care improvements in a financially constrained environmentInger Ekman, Reinhard Busse, Ewout van Ginneken, et al.
JAMA|June 12, 2008
Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fractionNorman C Wang, Aldo P Maggioni, Marvin A Konstam, et al.
Circulation|June 15, 2007
Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programEileen O'Meara, Tim Clayton, Margaret B McEntegart, et al.
Circulation. Heart Failure|February 27, 2016
Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) TrialScott D Solomon, Brian Claggett, Akshay S Desai, et al.
European Journal of Heart Failure|October 23, 2024
Visit-to-visit changes in heart rate in heart failure: A pooled participant-level analysis of the PARADIGM-HF and PARAGON-HF trialsHenri Lu, Brian L Claggett, Milton Packer, et al.
European Journal of Heart Failure|May 16, 2023
Incremental prognostic value of biomarkers in PARADIGM-HFKirsty McDowell, Ross Campbell, Joanne Simpson, et al.
Circulation. Heart Failure|May 4, 2016
Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST TrialAndrew P Ambrosy, Hassan Khan, James E Udelson, et al.
Pageof 48